小鼠非酒精性脂肪性肝炎中线粒体功能的障碍

doi:10.12066/j.issn.1007-2861.2086

Abstract

Abstract:

[Objective] This research is to study the changes of mitochondrial function in non-alcoholic steatohepatitis (NASH). [Methods] The method is to use C57BL/6 mice fed with choline methionine deficient (MCD) diet to induce a mouse NASH model. The choline methionine sufficient (MCS) group serves as the control group. Four weeks later, serum and liver tissue are detected when mice are sacrificed. Biochemical indicators of serum alanine aminotransferase (ALT) activity, aspartate aminotransferase (AST) activity, liver triglyceride (TG), total cholesterol (TC) levels are detected by enzymelinked immunosorbent assay. Pathological examination has also been performed. The mtDNA/nDNA and nDNA in liver tissue of mice and the expression of genes encoded by mitochondrial DNA, mitochondrial DNA replication and associated with energy metabolism in mouse liver are tested by qRT-PCR (quantificational real-time polymerase chain reaction). [Results] Compared with the MCS group, the MCD model group shows severe degeneration of liver tissue, and ALT, AST, and TG become significantly elevated, but TC levels are decreased. A large amount of fat vacuoles, severe destruction of lobular structure, and significant infiltration of inflammatory cells become increased in MCD model. In addition, the amount of mitochondrial is decreased. Furthermore, the capacity of energy metabolism and DNA repair of the MCD model group are significantly reduced. [Conclusion] Mitochondrial dysfunction occurs in mice with non-alcoholic steatohepatitis.

Key words: non-alcoholic steatohepatitis (NASH), mitochondria, energy metabolism

CLC Number:

G804.5

HOU Wenlin, PAN Wen, FU Siyi, SONG Meiyi, WANG Fei. Dysfunction of mitochondrial in mice with non-alcoholic steatohepatitis[J]. Journal of Shanghai University（Natural Science Edition）, 2019, 25(1): 1-9.

Figures/Tables 6

Table 1

Table 2

Fig.1

Fig.2

Fig.3

Fig.4

References 20

[1]	Bjornsson E, Angulo P . Non-alcoholic fatty liver disease[J]. Scand J Gastroenterol, 2007,42(9):1023-1030.
[2]	Hubscher S G . Histological assessment of non-alcoholic fatty liver disease[J]. Histopathology, 2006,49(5):450-465.
[3]	Neuschwander-Tetri B A, Clark J M, Bass N M , et al. Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease[J]. Hepatology, 2010,52(3):913-924.
[4]	Chalasani N, Younossi Z, Lavine J E , et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases[J]. Hepatology, 2018,67(1):328-357.
[5]	Bellentani S . The epidemiology of non-alcoholic fatty liver disease[J]. Liver Int, 2017,37(S1):81-84.
[6]	Cohen J C, Horton J D, Hobbs H H . Human fatty liver disease: old questions and new insights[J]. Science, 2011,332(37):1519-1523.
[7]	Pessayre D, Fromenty B . NASH: a mitochondrial disease[J]. J Hepatol, 2005,42(6):928-940.
[8]	Koch L . Metabolism: mitochondrial pathways in NAFLD[J]. Nat Rev Endocrinol, 2012,8(3):129.
[9]	Huttenlocher P R, Solitare G B, Adams G . Infantile diffuse cerebral degeneration with hepatic cirrhosis[J]. Arch Neurol, 1976,33(3):186-192.
[10]	Gomez-Zorita S, Fernandez-Quintela A, Macarulla M T , et al. Resveratrol attenuates steatosis in obese Zucker rats by decreasing fatty acid availability and reducing oxidative stress[J]. Br J Nutr, 2012,107(2):202-210.
[11]	Rizki G, Arnaboldi L, Gabrielli B , et al. Mice fed a lipogenic methionine-choline-deficient diet develop hypermetabolism coincident with hepatic suppression of SCD-1[J]. J Lipid Res, 2006,47(10):2280-2290.
[12]	Lee G S, Yan J S, Ng R K , et al. Polyunsaturated fat in the methionine-choline-deficient diet influences hepatic inflammation but not hepatocellular injury[J]. J Lipid Res, 2007,48(8):1885-1896.
[13]	Lin J, Wu H, Tarr P T , et al. Transcriptional co-activator PGC-1 alpha drives the formation of slow-twitch muscle fibres[J]. Nature, 2002,418(6899):797-801.
[14]	Greenfield V, Cheung O, Sanyal A J . Recent advances in nonalcholic fatty liver disease[J]. Curr Opin Gastroenterol, 2008,24(3):320-327.
[15]	Kashi M R, Torres D M, Harrison S A . Current and emerging therapies in nonalcoholic fatty liver disease[J]. Semin Liver Dis, 2008,28(4):396-406.
[16]	Ioannou G N . The role of cholesterol in the pathogenesis of NASH[J]. Trends Endocrinol Metab, 2016,27(2):84-95.
[17]	Pariente A . Management of non alcoholic fatty liver diseases in adults[J]. Rev Prat, 2012,62(10):1421-1425.
[18]	Ding W X . Role of autophagy in liver physiology and pathophysiology[J]. World J Biol Chem, 2010,1(1):3-12.
[19]	Basaranoglu M, Basaranoglu G, Senturk H . From fatty liver to fibrosis: a tale of "second hit"[J]. World J Gastroenterol, 2013,19(8):1158-1165.
[20]	Cortez-Pinto H, Chatham J, Chacko V P , et al. Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis: a pilot study[J]. JAMA Network, 1999,282(17):1659-1664.

Dysfunction of mitochondrial in mice with non-alcoholic steatohepatitis

RichHTML

PDF

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 6

References 20

Related Articles 1

Recommended Articles

Metrics

Comments